Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini–Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial
Sign Up to like & getrecommendations! Published in 2018 at "JAMA Oncology"
DOI: 10.1001/jamaoncol.2017.2380
Abstract: Importance The outcome of patients with relapsed or refractory (R/R) acute lymphoblastic leukemia (ALL) is poor. Inotuzumab ozogamicin, a CD22 monoclonal antibody bound to calicheamicin, has single-agent activity in R/R ALL. Objective To evaluate the… read more here.
Keywords: relapsed refractory; inotuzumab; salvage; acute lymphoblastic ... See more keywords
Safety and long‐term survival results of the addition of inotuzumab ozogamicin to the conditioning regimen of allogeneic stem cell transplantation: A single‐center phase 1,2 trial
Sign Up to like & getrecommendations! Published in 2024 at "American Journal of Hematology"
DOI: 10.1002/ajh.27254
Abstract: Here we report on the first prospective study evaluating the safety and long‐term survival when an escalating dose of inotuzumab ozogamicin (INO) (0.6, 1.2, or 1.8 mg/m2 on day 13) was added to one alkylator‐containing conditioning… read more here.
Keywords: conditioning regimen; survival; inotuzumab ozogamicin; long term ... See more keywords
Assessment of liver stiffness measurement and ultrasound findings change during inotuzumab ozogamicin cycles for relapsed or refractory acute lymphoblastic leukemia
Sign Up to like & getrecommendations! Published in 2021 at "Cancer Medicine"
DOI: 10.1002/cam4.4390
Abstract: In adult patients, acute lymphoblastic leukemia (ALL) is a rare hematological cancer with a cure rate below 50% and frequent relapses. With traditional therapies, patients with relapsed or refractory (R/R) ALL have a survival that… read more here.
Keywords: relapsed refractory; liver; inotuzumab ozogamicin; acute lymphoblastic ... See more keywords
INO‐CD22: A multicenter, real‐world study of inotuzumab ozogamicin safety and effectiveness in adult patients with relapsed/refractory acute lymphoblastic leukemia
Sign Up to like & getrecommendations! Published in 2025 at "Cancer"
DOI: 10.1002/cncr.35820
Abstract: Inotuzumab ozogamicin (IO) has helped to change the treatment paradigm in B‐cell acute lymphoblastic leukemia (B‐ALL) but real‐world data are limited. read more here.
Keywords: acute lymphoblastic; lymphoblastic leukemia; real world; inotuzumab ozogamicin ... See more keywords
Liver Complications Following Treatment of Hematologic Malignancy With Anti‐CD22‐Calicheamicin (Inotuzumab Ozogamicin)
Sign Up to like & getrecommendations! Published in 2019 at "Hepatology"
DOI: 10.1002/hep.30222
Abstract: Treatment of hematological malignancy with antibody‐drug conjugates (ADCs) may cause liver injury. ADCs deliver a toxic moiety into antigen‐expressing tumor cells, but may also injure hepatic sinusoids (sinusoidal obstruction syndrome; SOS). We studied patients who… read more here.
Keywords: treatment; anti cd22; liver; malignancy ... See more keywords
Inotuzumab ozogamicin versus standard of care in Asian patients with relapsed/refractory acute lymphoblastic leukemia
Sign Up to like & getrecommendations! Published in 2019 at "International Journal of Hematology"
DOI: 10.1007/s12185-019-02749-0
Abstract: Inotuzumab ozogamicin (InO) is a targeted treatment for adults with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). InO was previously studied in INO-VATE, an international, open-label, randomized phase 3 trial comparing InO against standard… read more here.
Keywords: relapsed refractory; asian patients; lymphoblastic leukemia; ino ... See more keywords
Population Pharmacokinetics of Inotuzumab Ozogamicin in Pediatric Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia: Results of Study ITCC-059
Sign Up to like & getrecommendations! Published in 2024 at "Clinical Pharmacokinetics"
DOI: 10.1007/s40262-024-01386-z
Abstract: Inotuzumab ozogamicin is an antibody-drug conjugate approved for treating relapsed/refractory B-cell precursor acute lymphoblastic leukemia (BCP-ALL) in adults. Pediatric pharmacokinetic data of inotuzumab ozogamicin are lacking. This study is the first to examine the population… read more here.
Keywords: time; inotuzumab ozogamicin; population; relapsed refractory ... See more keywords
Primary refractory B-cell lymphoblastic leukemia with extramedullary disease – a distinctive response to blinatumomab and inotuzumab ozogamicin
Sign Up to like & getrecommendations! Published in 2019 at "Hematology, Transfusion and Cell Therapy"
DOI: 10.1016/j.htct.2018.11.004
Abstract: Historically, refractory/relapsed (r/r) acute B-lymphoblastic leukemia (ALL) in adults has a dismal prognosis, with less than 10% of patients being long-term survivors, which is only achievable through a bone marrow (BM) transplantation.1 The emergence of… read more here.
Keywords: cell; disease; lymphoblastic leukemia; refractory ... See more keywords
Incidence of Subsequent Lumbar Surgery Following Posterior Lumbar Fusion
Sign Up to like & getrecommendations! Published in 2018 at "Value in Health"
DOI: 10.1016/j.jval.2018.04.710
Abstract: system (FAERS) database. A retrospective descriptive analysis was conducted to explore the frequency of VOD in all patients who had taken GO and Inotuzumab Ozogamicin and reported adverse event to FDA from 2000 to 2016.… read more here.
Keywords: death; vod; reports vod; lumbar ... See more keywords
Treatment of Recurrent Refractory Pediatric Pre-B Acute Lymphoblastic Leukemia Using Inotuzumab Ozogamicin Monotherapy Resulting in CD22 Antigen Expression Loss as a Mechanism of Therapy Resistance
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Pediatric Hematology/Oncology"
DOI: 10.1097/mph.0000000000001440
Abstract: Background: Inotuzumab ozogamicin is a novel antibody-drug conjugate that targets CD22, a common antigen on pre-B acute lymphoblastic leukemia cells. Observations: A 7-year-old boy with pre-B acute lymphoblastic leukemia in his second relapse was given… read more here.
Keywords: pre acute; acute lymphoblastic; lymphoblastic leukemia; inotuzumab ozogamicin ... See more keywords
Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22
Sign Up to like & getrecommendations! Published in 2021 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-20-2399
Abstract: Purpose: We assessed the relationship between cluster of differentiation-22 (CD22) expression and outcomes of inotuzumab ozogamicin versus standard of care (SC) in INO-VATE (NCT01564784). Patients and Methods: Adults with relapsed/refractory B-cell precursor CD22-positive (by local… read more here.
Keywords: ozogamicin versus; cd22 positivity; inotuzumab ozogamicin; cd22 ... See more keywords